Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 5203 | 11.15 |
09:34 ET | 102189 | 11.26 |
09:36 ET | 9300 | 11.11 |
09:38 ET | 512 | 11.15 |
09:39 ET | 202 | 11.145 |
09:41 ET | 470 | 11.155 |
09:43 ET | 1985 | 11.175 |
09:45 ET | 2459 | 11.09 |
09:48 ET | 100 | 11.12 |
09:50 ET | 5975 | 11.01 |
09:52 ET | 16457 | 10.86 |
09:54 ET | 2733 | 10.9 |
09:56 ET | 5475 | 10.81 |
09:57 ET | 1246 | 10.81 |
09:59 ET | 6813 | 10.8644 |
10:01 ET | 3558 | 10.88 |
10:03 ET | 1055 | 10.895 |
10:06 ET | 5850 | 10.82 |
10:08 ET | 2413 | 10.81 |
10:10 ET | 626 | 10.81 |
10:12 ET | 3600 | 10.83 |
10:14 ET | 3419 | 10.85 |
10:15 ET | 100 | 10.85 |
10:17 ET | 600 | 10.82 |
10:19 ET | 100 | 10.85 |
10:21 ET | 2220 | 10.82 |
10:24 ET | 300 | 10.8599 |
10:26 ET | 1235 | 10.85 |
10:28 ET | 5787 | 10.92 |
10:30 ET | 1100 | 10.93 |
10:32 ET | 1600 | 10.965 |
10:33 ET | 1954 | 10.98 |
10:35 ET | 300 | 10.98 |
10:37 ET | 110650 | 11.155 |
10:39 ET | 1950 | 11.1812 |
10:42 ET | 3400 | 11.25 |
10:44 ET | 3042 | 11.15 |
10:46 ET | 2857 | 11.26 |
10:48 ET | 100 | 11.32 |
10:50 ET | 1091 | 11.3602 |
10:51 ET | 1462 | 11.36 |
10:53 ET | 2232 | 11.4386 |
10:55 ET | 762 | 11.45 |
11:00 ET | 1387 | 11.485 |
11:02 ET | 15723 | 11.46 |
11:04 ET | 6941 | 11.53 |
11:06 ET | 10467 | 11.58 |
11:08 ET | 1082 | 11.605 |
11:09 ET | 3427 | 11.55 |
11:11 ET | 9099 | 11.5481 |
11:13 ET | 3900 | 11.52 |
11:15 ET | 1256 | 11.55 |
11:18 ET | 1309 | 11.5 |
11:20 ET | 200 | 11.4601 |
11:26 ET | 1900 | 11.485 |
11:27 ET | 1500 | 11.5 |
11:29 ET | 500 | 11.515 |
11:31 ET | 100 | 11.515 |
11:33 ET | 3606 | 11.52 |
11:36 ET | 300 | 11.46 |
11:38 ET | 300 | 11.42 |
11:40 ET | 7587 | 11.38 |
11:44 ET | 1486 | 11.34 |
11:47 ET | 4445 | 11.39 |
11:49 ET | 300 | 11.36 |
11:51 ET | 1713 | 11.32 |
11:54 ET | 200 | 11.28 |
11:56 ET | 700 | 11.29 |
11:58 ET | 400 | 11.28 |
12:00 ET | 825 | 11.29 |
12:02 ET | 100 | 11.34 |
12:03 ET | 400 | 11.33 |
12:05 ET | 134 | 11.32 |
12:07 ET | 200 | 11.33 |
12:09 ET | 100 | 11.32 |
12:12 ET | 1600 | 11.24 |
12:16 ET | 500 | 11.25 |
12:18 ET | 306 | 11.27 |
12:20 ET | 863 | 11.265 |
12:21 ET | 100 | 11.27 |
12:23 ET | 100 | 11.275 |
12:25 ET | 100 | 11.275 |
12:27 ET | 200 | 11.26 |
12:30 ET | 600 | 11.275 |
12:32 ET | 200 | 11.25 |
12:34 ET | 500 | 11.2401 |
12:36 ET | 1388 | 11.18 |
12:38 ET | 700 | 11.2 |
12:41 ET | 100 | 11.21 |
12:43 ET | 2670 | 11.26 |
12:45 ET | 11392 | 11.345 |
12:48 ET | 100 | 11.325 |
12:50 ET | 1350 | 11.3 |
12:52 ET | 200 | 11.3 |
12:54 ET | 33827 | 11.33 |
12:56 ET | 800 | 11.29 |
12:57 ET | 2838 | 11.285 |
12:59 ET | 931 | 11.26 |
01:01 ET | 100 | 11.23 |
01:03 ET | 850 | 11.19 |
01:06 ET | 400 | 11.19 |
01:08 ET | 200 | 11.18 |
01:10 ET | 500 | 11.175 |
01:12 ET | 200 | 11.185 |
01:14 ET | 430 | 11.17 |
01:15 ET | 300 | 11.19 |
01:17 ET | 200 | 11.185 |
01:19 ET | 2750 | 11.165 |
01:21 ET | 700 | 11.105 |
01:24 ET | 3287 | 11.12 |
01:26 ET | 2124 | 11.1 |
01:28 ET | 255 | 11.09 |
01:30 ET | 2288 | 11.09 |
01:32 ET | 400 | 11.09 |
01:33 ET | 1500 | 11.03 |
01:35 ET | 300 | 11.03 |
01:37 ET | 3700 | 11 |
01:39 ET | 400 | 10.99 |
01:42 ET | 300 | 10.98 |
01:44 ET | 5059 | 10.945 |
01:46 ET | 3771 | 10.94 |
01:48 ET | 1705 | 10.9 |
01:50 ET | 400 | 10.88 |
01:51 ET | 1196 | 10.87 |
01:53 ET | 6361 | 10.87 |
01:55 ET | 6089 | 10.81 |
01:57 ET | 500 | 10.84 |
02:00 ET | 2349 | 10.83 |
02:02 ET | 4200 | 10.75 |
02:04 ET | 750 | 10.77 |
02:06 ET | 3499 | 10.795 |
02:08 ET | 500 | 10.78 |
02:09 ET | 4924 | 10.8 |
02:11 ET | 3402 | 10.83 |
02:13 ET | 1599 | 10.8 |
02:15 ET | 100 | 10.8 |
02:18 ET | 902 | 10.835 |
02:20 ET | 4346 | 10.87 |
02:22 ET | 2500 | 10.87 |
02:24 ET | 1150 | 10.9 |
02:26 ET | 1800 | 10.88 |
02:27 ET | 100 | 10.89 |
02:29 ET | 4649 | 10.85 |
02:31 ET | 100 | 10.8463 |
02:33 ET | 1249 | 10.84 |
02:36 ET | 1001 | 10.82 |
02:38 ET | 100 | 10.82 |
02:40 ET | 2324 | 10.8 |
02:42 ET | 300 | 10.76 |
02:44 ET | 1150 | 10.76 |
02:45 ET | 1790 | 10.77 |
02:47 ET | 10708 | 10.8 |
02:49 ET | 1038 | 10.77 |
02:51 ET | 1150 | 10.79 |
02:54 ET | 400 | 10.77 |
02:56 ET | 500 | 10.78 |
02:58 ET | 300 | 10.795 |
03:00 ET | 5250 | 10.76 |
03:02 ET | 400 | 10.76 |
03:03 ET | 3003 | 10.76 |
03:05 ET | 2565 | 10.76 |
03:07 ET | 5681 | 10.76 |
03:09 ET | 700 | 10.75 |
03:12 ET | 4528 | 10.75 |
03:14 ET | 5431 | 10.765 |
03:16 ET | 2489 | 10.76 |
03:18 ET | 13775 | 10.81 |
03:20 ET | 3279 | 10.8864 |
03:21 ET | 790 | 10.86 |
03:23 ET | 2226 | 10.8396 |
03:25 ET | 1378 | 10.825 |
03:27 ET | 6663 | 10.95 |
03:30 ET | 11820 | 10.95 |
03:32 ET | 6529 | 10.98 |
03:34 ET | 5247 | 10.865 |
03:36 ET | 5686 | 10.88 |
03:38 ET | 3267 | 10.86 |
03:39 ET | 5314 | 10.9 |
03:41 ET | 3533 | 10.86 |
03:43 ET | 2053 | 10.89 |
03:45 ET | 5738 | 10.8801 |
03:48 ET | 1548 | 10.89 |
03:50 ET | 2359 | 10.86 |
03:52 ET | 10977 | 10.95 |
03:54 ET | 6739 | 11.01 |
03:56 ET | 31484 | 11.01 |
03:57 ET | 26585 | 11.01 |
03:59 ET | 131351 | 11 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 395.4M | -3.1x | --- |
LENZ Therapeutics Inc | 400.9M | -1.0x | --- |
Terns Pharmaceuticals Inc | 388.1M | -4.8x | --- |
ACELYRIN Inc | 409.0M | -1.6x | --- |
Fibrobiologics Inc | 375.6M | -11.1x | --- |
Neurogene Inc | 416.8M | -7.0x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $395.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.